I. Paul Singh, MD; and Jason Bacharach, MD
Show Description +
Jason Bacharach, MD, joins host I. Paul Singh, MD, to discuss a study exploring patient-reported outcomes after switching to or starting a preservative-free latanoprost formulation. As Dr. Bacharach notes in this episode, in addition to contributing to ocular surface disease, drops containing benzalkonium chloride may impact the long-term health of the trabecular meshwork.
REFERENCES
PErb C, Stalmans I, Iliev M, Muñoz-Negrete FJ. Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost. Clin Ophthalmol. 2021 Mar 2;15:931-938. doi: 10.2147/OPTH.S295821. PMID: 33688161; PMCID: PMC7936704.
Posted: 11/25/2024
I. Paul Singh, MD; and Jason Bacharach, MD
Jason Bacharach, MD, joins host I. Paul Singh, MD, to discuss a study exploring patient-reported outcomes after switching to or starting a preservative-free latanoprost formulation. As Dr. Bacharach notes in this episode, in addition to contributing to ocular surface disease, drops containing benzalkonium chloride may impact the long-term health of the trabecular meshwork.
REFERENCES
PErb C, Stalmans I, Iliev M, Muñoz-Negrete FJ. Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost. Clin Ophthalmol. 2021 Mar 2;15:931-938. doi: 10.2147/OPTH.S295821. PMID: 33688161; PMCID: PMC7936704.
Posted: 11/25/2024
Supported by
Please log in to leave a comment.